4//SEC Filing
Pauza Charles David 4
Accession 0000929638-24-001364
CIK 0001130598other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 8:04 PM ET
Size
10.0 KB
Accession
0000929638-24-001364
Insider Transaction Report
Form 4
Pauza Charles David
Chief Science Officer Virology
Transactions
- Award
Common Stock
2024-04-01+97,500→ 97,500 total - Award
Stock Option (right to purchase)
2024-04-01+333,136→ 333,136 totalExercise: $0.07From: 2023-11-01Exp: 2033-10-31→ Common Stock (333,136 underlying) - Award
Stock Option (right to purchase)
2024-04-01+503,227→ 503,227 totalExercise: $0.01From: 2023-11-01Exp: 2033-10-31→ Common Stock (503,227 underlying)
Footnotes (4)
- [F1]Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company"), par value $0.01 per share ("Common Stock"), on a one-for-one basis.
- [F2]On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.
- [F3]Received in the Merger in exchange for stock options to acquire 16,550 shares of Trawsfynydd common stock with an exercise price of $1.38 per share.
- [F4]Received in the Merger in exchange for stock options to acquire 25,000 shares of Trawsfynydd common stock with an exercise price of $0.0001 per share.
Documents
Issuer
Traws Pharma, Inc.
CIK 0001130598
Entity typeother
Related Parties
1- filerCIK 0002018150
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 8:04 PM ET
- Size
- 10.0 KB